Editas Medicine
James Mullen takes over as CEO from Feb. 15.
Editas chairman Mullen will don the CEO mantle Feb. 15, taking over for current Editas chief
Cynthia Collins. Before jumping to the Editas team, Mullen was CEO and director of the CDMO Patheon later snapped up by Thermo Fisher and also served as the CEO of Biogen. In a brief release, Editas didn’t say why Collins was leaving. “It has been a privilege to lead Editas Medicine and this extremely talented team,” she said in a statement. “I am particularly proud of the progress to the clinic we have made with both in vivo and ex vivo gene edited medicines.” Collins joined Editas in 2019, picking up the role from
Search jobs jCyte Announces Promotion of Dr. Shannon Blalock to Chief Executive Officer
- Dr. Blalock brings more than 25 years of commercialization and operational expertise as jCell therapy advances toward its pivotal Phase 3 clinical trial program.
NEWPORT BEACH, Calif. (BUSINESS WIRE) jCyte Inc., a biotech company dedicated to improving the lives of patients with retinal degenerative diseases, today announced the Board of Directors has promoted Dr. Shannon Blalock to Chief Executive Officer and an elected member of the Board. Dr. Blalock joined jCyte last year as its Chief Operating Officer.
“I am thrilled to announce the appointment of Shannon as jCyte’s new CEO at this important point in the company’s evolution. Shannon has contributed significantly to our company since joining jCyte last year. His outstanding operational expertise and corporate leadership experience will be invaluable as we advance our transformative jCell therapy, which rec